FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168045341> ?p ?o ?g. }

• W3168045341 endingPage "579" @default.
• W3168045341 startingPage "572" @default.
• W3168045341 abstract "Objective: This study intends to explore the difference in the efficacy of PCSK9 inhibitors in patients with different FH phenotypes by analyzing the level of blood lipids before and after treatment with PCSK9 inhibitors in patients with familial hypercholesterolemia (FH) with different allele grades. Methods: Patients with FH phenotype, who admitted to Beijing Anzhen Hospital from January 2019 to October 2020, were enrolled. Age, sex and other clinical information were collected from enrolled, and the pathogenic genes were detected by the second generation sequencing technique. The patients were divided into five groups according to the number of alleles involved and the degree of gene damage: single allele-null mutation group, single allele-defect mutation group, multi-allele-null mutation group, multi-allele-defect mutation group and no major pathogenic gene mutation group. The results of blood lipids were collected before medication, 4-6 weeks of intensive statin treatment and one month after combined treatment with PCSK9 inhibitor (PCSK9i). The LDL-C level were compared among groups. ASCVD risk stratification was performed in all patients, and the proportion of LDL-C level reaching the corresponding risk stratification target value of each genotype group after treatment was analyzed. Results: A total of 66 patients with FH phenotype were included, including 47 males (71.2%) and 19 females (28.8%),the mean age was(43.1±13.4 years). There were 7 cases in single allele-null mutation group (10.6%), 25 cases in single allele-defect mutation group (37.9%), 8 cases in multi-allele-null mutation group (12.1%), 18 cases in multi-allele-defect mutation group (27.3%) and 8 cases in no major pathogenic mutation group (12.1%). The degree of LDL-C reduction post combined PCSK9 inhibitor therapy was as follows: single allele mutation group>no major pathogenic mutation group>multi-allele mutation group, general distribution was in the range of 0-90.0%. Two groups of single allele mutation and no major pathogenic mutation group>50.0%>multi-allele mutation group. Under the combined treatment of PCSK9 inhibitors, the further decrease of LDL-C was in the order of single allele mutation group>non-major pathogenic mutant group>multi-allele mutation group. The efficacy of combined therapy on reducing LDL-C at 1 month after treatment decreased with the increase of baseline LDL-C level (r = 0.46, P<0.001) in patients with FH phenotype. In addition, the further decrease of LDL-C level post high-intensity statin therapy combined with PCSK9 inhibitors decreased with the increase of baseline LDL-C levels (r = 0.40, P<0.001). The degree of LDL-C decrease was high and stable by statin combined with PCSK9 inhibitor therapy in single allele mutation group. In the single allele-defect mutant group, the decrease of LDL-C increased with the increase of baseline LDL-C level post intensive statin treatment and combined PCSK9 inhibitor treatment ((r=0.54, P=0.009); r=0.45,P=0.030), and the further decrease of LDL-C level decreased with the increase of baseline LDL-C level in single allele-defect mutant group post combined therapy with PCSK9 inhibitor (r=0.43, P=0.040). The decrease of LDL-C in patients with the multi-allele mutation group varied with different pathogenic gene loci and combinations post combined therapy with PCSK9 inhibitor. There was no significant difference in the level of blood lipids between the group without major pathogenic gene mutation and the group with single allele mutation before and after treatment. The percentage of patients achieving LDL-C goals with different genotypes of phenotypic FH were as follows: single allele mutation group (86.7%), non-major pathogenic mutant group (75.0%) and multi-allele mutation grou (<5.0%). Conclusions: All patients with different FH phenotypes could benefit from the intensive lipid-lowering therapy with statins and PCSK9 inhibitors, however, there are significant differences in the efficacy of lowering LDL-C in Chinese patients with FH phenotype with different molecular etiologies. Therefore, the pathogenic gene analysis may suggest the lipid-lowering effect of PCSK9 inhibitors in patients with FH." @default.
• W3168045341 created "2021-06-22" @default.
• W3168045341 creator A5010434159 @default.
• W3168045341 creator A5012176187 @default.
• W3168045341 creator A5043129946 @default.
• W3168045341 creator A5060314863 @default.
• W3168045341 creator A5069230386 @default.
• W3168045341 creator A5073983062 @default.
• W3168045341 creator A5088421513 @default.
• W3168045341 date "2021-06-24" @default.
• W3168045341 modified "2023-09-22" @default.
• W3168045341 title "The relationship between genotype of familial hypercholesterolemia and the efficacy of PCSK9 inhibitors" @default.
• W3168045341 doi "https://doi.org/10.3760/cma.j.cn112148-20210322-00257" @default.
• W3168045341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34126724" @default.
• W3168045341 hasPublicationYear "2021" @default.
• W3168045341 type Work @default.
• W3168045341 sameAs 3168045341 @default.
• W3168045341 citedByCount "1" @default.
• W3168045341 countsByYear W31680453412023 @default.
• W3168045341 crossrefType "journal-article" @default.
• W3168045341 hasAuthorship W3168045341A5010434159 @default.
• W3168045341 hasAuthorship W3168045341A5012176187 @default.
• W3168045341 hasAuthorship W3168045341A5043129946 @default.
• W3168045341 hasAuthorship W3168045341A5060314863 @default.
• W3168045341 hasAuthorship W3168045341A5069230386 @default.
• W3168045341 hasAuthorship W3168045341A5073983062 @default.
• W3168045341 hasAuthorship W3168045341A5088421513 @default.
• W3168045341 hasConcept C104317684 @default.
• W3168045341 hasConcept C126322002 @default.
• W3168045341 hasConcept C135763542 @default.
• W3168045341 hasConcept C180754005 @default.
• W3168045341 hasConcept C2778163477 @default.
• W3168045341 hasConcept C2779120738 @default.
• W3168045341 hasConcept C2780072125 @default.
• W3168045341 hasConcept C2780948078 @default.
• W3168045341 hasConcept C43554185 @default.
• W3168045341 hasConcept C54355233 @default.
• W3168045341 hasConcept C57708383 @default.
• W3168045341 hasConcept C71924100 @default.
• W3168045341 hasConcept C86803240 @default.
• W3168045341 hasConcept C90924648 @default.
• W3168045341 hasConceptScore W3168045341C104317684 @default.
• W3168045341 hasConceptScore W3168045341C126322002 @default.
• W3168045341 hasConceptScore W3168045341C135763542 @default.
• W3168045341 hasConceptScore W3168045341C180754005 @default.
• W3168045341 hasConceptScore W3168045341C2778163477 @default.
• W3168045341 hasConceptScore W3168045341C2779120738 @default.
• W3168045341 hasConceptScore W3168045341C2780072125 @default.
• W3168045341 hasConceptScore W3168045341C2780948078 @default.
• W3168045341 hasConceptScore W3168045341C43554185 @default.
• W3168045341 hasConceptScore W3168045341C54355233 @default.
• W3168045341 hasConceptScore W3168045341C57708383 @default.
• W3168045341 hasConceptScore W3168045341C71924100 @default.
• W3168045341 hasConceptScore W3168045341C86803240 @default.
• W3168045341 hasConceptScore W3168045341C90924648 @default.
• W3168045341 hasIssue "6" @default.
• W3168045341 hasLocation W31680453411 @default.
• W3168045341 hasOpenAccess W3168045341 @default.
• W3168045341 hasPrimaryLocation W31680453411 @default.
• W3168045341 hasRelatedWork W1972966844 @default.
• W3168045341 hasRelatedWork W1985904950 @default.
• W3168045341 hasRelatedWork W1986374757 @default.
• W3168045341 hasRelatedWork W2000478525 @default.
• W3168045341 hasRelatedWork W2087278907 @default.
• W3168045341 hasRelatedWork W2127833331 @default.
• W3168045341 hasRelatedWork W2179697345 @default.
• W3168045341 hasRelatedWork W2332693637 @default.
• W3168045341 hasRelatedWork W2348097073 @default.
• W3168045341 hasRelatedWork W2357476462 @default.
• W3168045341 hasRelatedWork W2406873597 @default.
• W3168045341 hasRelatedWork W2467525619 @default.
• W3168045341 hasRelatedWork W2742021505 @default.
• W3168045341 hasRelatedWork W2763697308 @default.
• W3168045341 hasRelatedWork W2803189008 @default.
• W3168045341 hasRelatedWork W2891882014 @default.
• W3168045341 hasRelatedWork W3024957253 @default.
• W3168045341 hasRelatedWork W3027340250 @default.
• W3168045341 hasRelatedWork W3132994518 @default.
• W3168045341 hasRelatedWork W3145036038 @default.
• W3168045341 hasVolume "49" @default.
• W3168045341 isParatext "false" @default.
• W3168045341 isRetracted "false" @default.
• W3168045341 magId "3168045341" @default.
• W3168045341 workType "article" @default.